natgillin/translations-raw huggingface dataset:
Congestive heart failure was observed in 0.5% of subjects in each treatment arm.
Kongestivno srčno popuščanje so opazili pri 0,5 % preiskovancev, ki so prejemali pazopanib in 0,5 % preiskovancev, ki so prejemali sunitinib.
Congestive heart failure was reported in 3 out of 240 subjects (1%) in the Phase III VEG110727 STS study.
V fazi III VEG110727 STS študije je bilo kongestivno srčno popuščanje opisano pri 3 od 240 preiskovancev (1 %).
congestive heart failure, abnormal heart rhythm, pericarditis (inflammation of the lining of the heart), inflammation and degeneration of muscle tissue and peripheral nerves, kidney problems, sarcoidosis (a disease characterized by persistent fever, weight loss, joint pain and swelling, skin lesions and swollen glands).
kongestivno srčno popuščanje, motnje srčnega ritma, perikarditis (vnetje osrčnika), vnetje in degeneracija mišičnega tkiva in perifernih živcev, ledvične težave, sarkoidoza (bolezen, za katero so značilni trdovratno zvišana telesna temperatura, hujšanje, bolečine in otekanje sklepov, kožne spremembe in otekle bezgavke).
Congestive heart failure, pericardial effusion, arrhythmia
kongestivno srčno popuščanje, perikardni izliv, aritmija
Congestive heart failure.
Kongestivno srčno popuščanje.
Congestive heart failure/
Kongestivno srčno
congestive heart failure/cardiac dysfunction*c, pericardial effusion*, arrhythmia (including tachycardia), palpitations
kongestivno srčno popuščanje/srčna disfunkcija*c, perikardialni izliv*, aritmije (vključno s tahikardijo), palpitacije
congestive heart failure/pulmonary oedema
kongestivno srčno popuščanje/pljučni edem
Congestive heart failurea,b, Supraventricular tachycardia
kongestivno srčno popuščanje a,b, supraventriku- larna tahikardija
CONITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
POGOJI IN OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
conivaptan – diuretic (used to increase low blood sodium levels) boceprevir, telaprevir – antiviral (used to treat Hepatitis C)
konivaptan – diuretik (uporablja se za zviševanje nizkih ravni natrija v krvi) boceprevir, telaprevir – protivirusno zdravilo (uporablja se za zdravljenje hepatitisa C)
Conjugated oestrogens tablet core
Jedro tablete s konjugiranimi estrogeni
Conjugated to Corynebacterium diphtheriae CRM197 protein 16.7 to 33.3 micrograms
Vezano na beljakovino CRM197 bakterije Corynebacterium diphtheriae 16,7 do 33,3 mikrogramov
Conjugated to CRM197 carrier protein and adsorbed on aluminium phosphate (0.125 mg aluminium).
ki so konjugirani na nosilni protein CRM197 in adsorbirani na aluminijev fosfat (0,125 mg aluminija).
Conjunctival
teklovini,
Conjunctival adhesion, conjunctival hyperaemia, corneal oedema, corneal perforation, eye irritation,
adhezija veznice, hiperemija veznice, edem roženice, perforacija roženice, draženje očesa, fotofobija
Conjunctival haemorrhage
krvavitev očesne veznice
Conjunctival haemorrhage Accommodation disorder Blindness
konjunktivalna krvavitev motnja akomodacije
Conjunctival haemorrhage, diplopia
krvavitev veznice, diplopija
Conjunctival haemorrhage, eye haemorrhage, corneal epithelium defect, eye pain, glaucoma/intraocular pressure increased, ulcerative keratitis
krvavitev v veznico, krvavitev v oko, okvara roženičnega
Conjunctival haemorrhage, eye pruritus, keratitis, vision blurred, photophobia
krvavitev v očesno veznico, pruritus očesa, keratitis, zamegljen vid, fotofobija
conjunctival hyperaemia
hiperemija veznice
conjunctival hyperaemia
konjunktivna hiperemija
conjunctival hyperaemia (mostly trace to mild and thought to be of a non-inflammatory nature) in up to 44% in the first year with the incidence of new reports decreasing to 13% at 2 years and 12% at 3 years ocular pruritus in up to 14% of patients in the first year with the incidence of new reports decreasing to 3% at 2 years and 0% at 3 years.
hiperemija veznice (najpogosteje komaj opazna do blaga in domnevno nevnetna) pri do 44 % bolnikov v prvem letu, z upadom števila novih poročil na 13 % pri 2 letih in 12 % pri 3 letih, okularni pruritus pri do 14 % bolnikov v prvem letu, z upadom števila novih poročil na 3 % pri 2 letih in 0 % pri 3 letih.
Conjunctival hyperaemia Abnormal sensation in eye Ocular discomfort
hiperemija veznice, nenormalen občutek v očesu, neprijeten občutek v očesu
Conjunctival hyperaemia Eye irritation,
krogov, očesni edem, oteklost oči,
Conjunctival hyperaemia,
veznice,
conjunctival hyperaemia, ocular pruritus, growth of eyelashes
hiperemija veznice, očesni pruritus, rast trepalnic
conjunctival hyperaemia.
hiperemija očesne veznice
Conjunctival irritation
Draženje veznice
Conjunctival oedema, lacrimal disorder, eye discharge, eye pruritus, conjunctival irritation, conjunctivitis, foreign body sensation in eyes, deposit eye, keratitis, blepharitis, corneal decompensation, chalazion, corneal infiltrates, corneal scar, eyelid pruritus, iridocyclitis.
edem veznice, motnje solzenja, izcedek iz očesa, očesni pruritus, draženje veznice, konjunktivitis, občutek tujka v očesu, depozit v očesu, keratitis, blefaritis, roženična dekompenzacija, halacij, roženični infiltrati, roženične brazgotine, pruritus veke, iridociklitis
Conjunctival/Scleral haemorrhage
krvavitev v veznici/beločnici
Conjunctivitis
Konjunktiviti s
Conjunctivitis
konjunktivitis,
Conjunctivitis
občasni:
conjunctivitis (a type of eye inflammation)
konjuktivitis (vrsta vnetja očesa),
conjunctivitis (an inflammation of the eye), eye irritation
konjunktivitis (vnetje očesa), draženje oči,
Conjunctivitis (G3/4:
konjunktivitis (S 3/4:
Conjunctivitis (G3/4:
konjunktivitis (S3/4:
Conjunctivitis (G3/4:
Močnejše solzenje
Conjunctivitis (G3/4: < 0.1%)
konjunktivitis (S3/4: < 0,1 %)
Conjunctivitis (G3/4: <0.1%)
konjunktivitis (S3/4: <0,1 %)
Conjunctivitis (including conjunctivitis, lacrimal disorder)
konjunktivitis (vključno s konjunktivitisom, motnjami solzenja)
Conjunctivitis (including red eyes, eye discharge and eye pain)
konjunktivitis (vključno z rdečimi očmi, izcedkom iz oči in bolečimi očmi)
conjunctivitis (inflamed eye)
konjunktivitis (vnetje očesa)
conjunctivitis (inflammation of the conjuntiva of the eyes)
konjunktivitis (vnetje očesne veznice)
Conjunctivitis (red eyes and discharge or pain in the eye)
konjunktivitis (rdeče oko in izcedek iz očesa ali bolečina v očesu)
Conjunctivitis (red eyes and discharge or pain in the eye)
konjunktivitis (rdeče oko in izcedek iz očesa ali bolečina v očesu),
Conjunctivitis Dry eye
konjunktivitis suho oko
Conjunctivitis Eye irritation
konjunktivitis draženje oči
Conjunctivitis Miosis
konjuktivitis mioza
Conjunctivitis, blepharitis, and dry eye*, mainly mild (CTC grade 1).
Konjunktivitis, blefaritis in suho oko*, v glavnem blagi (1. stopnja po CTC)
Conjunctivitis, corneal opacity, keratitis, photophobia, eye pain
konjunktivitis, motnjava roženice, keratitis, fotofobija, bolečine v očeh
Conjunctivitis, Eye
vnetje oči
Conjunctivitis, Eye discharge, Eyelid inflammation, Eye irritation, Eye swelling, Ocular hyperaemia, Tearing, Visual discomfort
konjunktivitis, izcedek iz oči, vnetje očesne veke, draženje oči, otekanje oči, hiperemija zrkla, solzenje, neprijeten občutek v očeh
Conjunctivitis, eye pain
konjunktivitis, bolečina v očesu
Conjunctivitis, eye pain
Občasni konjunktivitis, bolečine v očeh
Conjunctivitis, eye pain
vnetje očesne veznice (konjunktivitis), bolečina v očesu
Conjunctivitis, eye pain, abnormal vision, lacrimal gland disorder
konjunktivitis, boleče oči, motnje vida, bolezni solzne žleze
Conjunctivitis, maculopathy, photophobia
konjunktivitis, makulopatija, fotofobija
Conjunctivitis, ocular haemorrhage, retinal artery or vein occlusion
konjunktivitis, očesna krvavitev, zapora mrežnične arterije ali vene
Conjunctivitis, Retinitis
konjunktivitis, retinitis
Conjunctivitis, vision abnormal, lacrimal gland disorder, eye
konjunktivitis, motnje vida, motnje solznih žlez, očesne
Conjunctivitis1, corneal opacity1
konjunktivitis1, motnost roženice1
Connect a sterile 10 cc or larger luer lock syringe to one opening (port) in the syringe connector and the ReFacto AF pre-filled syringe to the remaining open port on the opposite end.
Privijte sterilno 10 cm3 ali večjo brizgo z Luer nastavkom na eno odprtino (vhod) na spojniku za brizge, napolnjeno injekcijsko brizgo zdravila ReFacto AF pa na drugi prosti vhod na nasprotni strani.
Connect one end of the transfer needle to the vaccine bottle of Ingelvac MycoFLEX.
Povežite en konec igle za prenos s plastenko s cepivom, ki vsebuje Ingelvac MycoFLEX.
Connect the female luer-lock of the gas tube (with the 0.2 μm bacteriostatic filter) to a pressure regulator.
Ženski priključek luer lock na cevi za plin (z 0,2-mikrometrskim bakteriostatskim filtrom) priključite na regulator tlaka.
Connect the infusion line and prime it with Erbitux before starting the infusion.
Preden začnete z dajanjem infuzije, priključite infuzijsko linijo in jo napolnite z razredčenim zdravilom Erbitux.
Connect the infusion line to the syringe, set and control the rate as explained in section 4.2 and start the infusion after priming the line with Erbitux or sterile sodium chloride 9 mg/mL (0.9%) solution.
Priključite infuzijsko linijo na brizgo, nastavite in nadzirajte hitrost infuzije, kot je opisano v poglavju 4.2, in po polnjenju linije začnite z infundiranjem zdravila Erbitux ali sterilne raztopine natrijev klorid 9 mg/ml (0,9%) raztopina za injiciranje.
Connect the infusion set with NovoRapid PumpCart by attaching the adapter onto your pump.
Povežite komplet za infundiranje z zdravilom NovoRapid PumpCart, tako da namestite nastavek na insulinsko črpalko.
Connect the other end of the filter to the injection set (e.g. butterfly / winged infusion needle or infusion catheter).
Drugi konec filtra povežite s pripomočkom za injiciranje (npr. metuljček/infuzijska igla s krilci ali infuzijski kateter).
Connect the plunger rod by screwing it clockwise into the syringe.
Vstavite potisni bat v injekcijsko brizgo s privijanjem v smeri gibanja urnega kazalca.
Connect the plunger rod by screwing it clockwise into the syringe.
Vstavite potisni bat v injekcijsko brizgo s privijanjem v smeri urnega kazalca.
Connect the plunger rod to the syringe by screwing it into the rubber stopper (E).
Bat brizge vstavite v injekcijsko brizgo s privijanjem v gumijast zamašek (E).
Connect the RaplixaSpray device to the ProFibrix air pressure regulator or CO2 pressure regulator and thereby to the medical air or CO2 gas supply set to a pressure setting of 1.5 bar (22 psi).
Pršilo zdravila Raplixa povežite z regulatorjem zračnega tlaka ProFibrix ali z regulatorjem tlaka CO2 in s tem z dovajanjem medicinskega zraka ali CO2, nastavljenim na tlak 1,5 bara (22 psi).
Connect the syringe to BAXJECT II / BAXJECT III.
Postavite brizgo na BAXJECT II / BAXJECT III.
Connect the syringe to the clear part of the transfer device and push the air in the syringe into the vial.
Priključite injekcijsko brizgo na prozorni del pribora za prenos vehikla in potisnite zrak iz injekcijske brizge v vialo.
Connect the syringe to the reconstitution spike and transfer the 10 ml of solvent into the vial of Rapilysin 10 U.
Injekcijsko brizgo pritrdite na pripomoček za pripravo in v vialo zdravila Rapilysin 10 enot prenesite 10 ml vehikla.
Connect the syringe to the vial adapter
Povežite brizgo z adapterjem za vialo.
Connect the transfer adapter onto the glass container by pushing it downwards until the transfer adapter is properly and securely placed
Na stekleničko nastavite nastavek za prenos in ga pritisnite nanjo.
Connections or passageways inside the body between internal organs and skin or other tissues (also called ‘fistula’): Common (may affect up to 1 in 10 people) - these abnormal tube-like connections or passageways can form for example, between the gut and your skin.
Povezave znotraj telesa med notranjimi organi in kožo ali drugimi tkivi (to imenujemo tudi "fistula"): pogosto (pojavijo se lahko pri največ 1 od 10 oseb) – Te nenormalne cevaste povezave lahko nastanejo na primer med črevesom in kožo.
Connections to the gas cylinder and to the ventilator patient breathing circuit
Priključitev na jeklenko in na napeljavo respiratorja za dihanje.
connective
istema in
connective tissue
istema in vezivnega tkiva
connective tissue
Pogostnost
Connective tissue metabolism
Presnova vezivnega tkiva
consciousness),
zavesti),
consciousness,
Očesne bolezni
Consecutive inhalation of three 1 mg unit dose blisters causes a significantly higher insulin exposure than inhalation of one 3 mg unit dose blister.
Izpostavljenost insulinu je po zaporedni inhalaciji treh 1-mg pretisnih omotov za enkratni odmerek bistveno večja kot po inhalaciji enega 3-mg pretisnega omota za enkratni odmerek.
Consequently, as a precautionary measure, breast-feeding is contra-indicated during and for at least 48 hours after treatment with blinatumomab.
Posledično, kot previdnostni ukrep, je dojenje kontraindicirano med obdobjem zdravljenja z blinatumomabom in vsaj še 48 ur po zdravljenju.
Consequently, caution is advised when Cymbalta is taken in combination with other centrally acting medicinal products or substances, including alcohol and sedative medicinal products (e.g. benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).
Zato je pri jemanju zdravila Cymbalta v kombinaciji z drugimi centralno delujočimi zdravili ali snovmi, ki vključujejo alkohol in pomirjevala (denimo benzodiazepini, morfinomimetiki, antipsihotiki, fenobarbital, sedirajoči antihistaminiki), potrebna previdnost.
Consequently, caution is advised when Duloxetine Lilly is taken in combination with other centrally acting medicinal products or substances, including alcohol and sedative medicinal products (e.g. benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).
Zato je pri jemanju zdravila Duloxetine Lilly v kombinaciji z drugimi centralno delujočimi zdravili ali snovmi, ki vključujejo alkohol in pomirjevala (denimo benzodiazepini, morfinomimetiki, antipsihotiki, fenobarbital, sedirajoči antihistaminiki), potrebna previdnost.
Consequently, caution is advised when Xeristar is taken in combination with other centrally acting medicinal products or substances, including alcohol and sedative medicinal products (e.g. benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).
Zato je pri jemanju zdravila Xeristar v kombinaciji z drugimi centralno delujočimi zdravili ali snovmi, ki vključujejo alkohol in pomirjevala (denimo benzodiazepini, morfinomimetiki, antipsihotiki, fenobarbital, sedirajoči antihistaminiki), potrebna previdnost.
Consequently, ciprofloxacin should not be taken at the same time, but at least 2 hours before or after Fexeric.
Ciprofloksacin se zato ne sme jemati sočasno, temveč vsaj 2 uri pred uporabo zdravila Fexeric ali 2 uri po njej.
Consequently, concomitant administration of ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4).
Zato sočasna uporaba ritonavirja, odmerjanegakot protiretrovirusno zdravilo ali kot farmakokinetični stopnjevalec, in teh glukokortikoidov ni priporočljiva, razen če možna korist terapije odtehta tveganja sistemskih učinkov kortikosteroidov (glejte
Consequently, concomitant administration of ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4).
Zato sočasna uporaba ritonavirja, odmerjanegakot protiretrovirusno zdravilo ali kot farmakokinetični stopnjevalec, in teh glukokortikoidov ni priporočljiva, razen če možna korist terapije odtehta tveganja sistemskih učinkov kortikosteroidov (glejte poglavje 4.4).
Consequently, concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole) should be approached with caution and concomitant administration with strong CYP3A4 inducers (e.g., rifampicin) should be avoided.
Zato je pri sočasnem dajanju z močnimi zaviralci CYP3A4 (npr. ketokonazol) potrebna previdnost, sočasnemu dajanju z močnimi spodbujevalci CYP3A4 (npr. rifampicin) pa se je treba izogibati.
Consequently, consideration should be given to longer treatment for patients with uncertain subsequent retreatment options.
Posledično je treba razmisliti o dolgotrajnejšem zdravljenju pri bolnikih z negotovimi možnostmi naknadnega ponovnega zdravljenja.
Consequently, Contacera’s benefit is taken as being the same as that of the reference medicine.
Zato velja, da so njegove koristi enake kot pri referenčnem zdravilu.
Consequently, in addition to antibodies to E. coli F5 (K99) it also contains antibodies to other organisms, as a result of vaccination and/or exposure of the donor cows to organisms in their environment.
Poleg protiteles proti E. coli F5 (K99) lahko posledično vsebuje tudi protitelesa na druge organizme, kar je posledica cepljenja ali/in izpostavljenja donorskih krav organizmom v njihovem okolju.
Consequently, INR should be closely monitored after initiating dronedarone in patients taking vitamin K antagonists as per their label.
Zato je pri bolnikih, ki v skladu z navodili jemljejo antagoniste vitamina K in začno jemati dronedaron, potrebno skrbno spremljati internacionalno normalizirano razmerje (INR).
Consequently, Loxicom’s benefit is taken as being the same as that of the reference medicinal product.
Zaradi tega velja, da so koristi zdravila Loxicom enake kot pri referenčnem zdravilu.
Consequently, newborns should be monitored for B-cell depletion and vaccinations with live virus vaccines should be postponed until the infant’s B-cell count has recovered (see section 4.4).
Posledično je treba novorojenčke spremljati glede izčrpanja celic B in cepljenja z živimi virusnimi cepivi odložiti, dokler se število celic B pri dojenčku ne povrne v normalno območje (glejte poglavje 4.4).
Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4).
Zato moramo biti previdni pri sočasni uporabi nesteroidnih protivnetnih zdravil, vključno z zaviralci COX- 2 in klopidogrela (glejte poglavje 4.4).
Consequently, patients with known risk factors for thromboembolism – including prior thrombosis – should be closely monitored.
Posledično je treba bolnike z znanimi dejavniki tveganja za trombembolijo, vključno s predhodnimi trombozami, skrbno spremljati.
Consequently, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.
Zato bolniki z redko dedno intoleranco na galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Consequently, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
Zato bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Consequently, Recocam’s benefit is taken as being the same as that of the reference medicine.
Zaradi tega velja, da so koristi zdravila Recocam enake kot pri referenčnem zdravilu.
Consequently, Renvela should not be taken simultaneously with ciprofloxacin.
Zato se zdravilo Renvela ne sme jemati istočasno s ciprofloksacinom.
Consequently, RevitaCAM’s benefit is taken as being the same as that of the reference medicine.
Zaradi tega velja, da so njegove koristi enake kot pri referenčnem zdravilu.
Consequently, Rheumocam’s benefit is taken as being the same as that of the reference medicine.
Zato velja, da so njegove koristi enake kot pri referenčnem zdravilu.
Consequently, Sevelamer carbonate Zentiva should not be taken simultaneously with ciprofloxacin.
Zato se zdravilo Sevelamer carbonate Zentiva ne sme jemati istočasno s ciprofloksacinom.
Consequently, should signs of pulmonary oedema occur when STAYVEER is administered in patients with PAH, the possibility of associated veno- occlusive disease should be considered.
Zato moramo v primeru, da se pri bolnikih s PAH, ko prejemajo zdravilo STAYVEER, pojavijo znaki pljučnega edema, pomisliti na možnost sočasne venookluzivne bolezni.
Consequently, the frequency of these adverse events is qualified as 'not known'.
Zato je pogostnost teh neželenih učinkov opredeljena kot “neznana”.
Consequently, the time-action profile of an insulin preparation is determined solely by its absorption characteristics.
Zato casovni potek delovanja pripravka insulina dolocajo samo njegove absorpcijske lastnosti.
Consequently, these infants may be at increased risk for infection.
Posledično je lahko pri teh dojenčki povečano tveganje za infekcije.
Consider a 25% dose reduction
Razmislite o zmanjšanju odmerka za 25
Consider adding supportive care as indicated.
Razmisliti je možno o dodatni podporni oskrbi, kot je indicirano.
Consider alternatives particularly for long-term use.
Razmisliti je treba o alternativnih oblikah zdravljenja, še posebej pri dolgotrajnem zdravljenju.
Consider discontinuing Iclusig
Razmislite o ukinitvi zdravljenja z zdravilom Iclusig
Consider dose escalation to 1.0 mg/m2 or further dose reduction to 0.5 mg/m2 in subsequent cycles based on patient tolerability.
Na osnovi bolnikovega prenašanja zdravljenja je treba pretehtati možnost povečanja odmerka na 1,0 mg/m2 ali
Consider dose escalation to 1.0 mg/m2 or further dose reduction to 0.5 mg/m2 in subsequent cycles based on patient tolerability.
Na osnovi bolnikovega prenašanja zdravljenja je treba pretehtati možnost povečanja odmerka na 1,0 mg/m2 ali zmanjšanja odmerka na 0,5 mg/m2.
Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or
e rifabutin daje 2- ali 3-krat na
Consider interruption of Tecfidera in patients with lymphocyte counts <0.5x109/L persisting for more than 6 months.
O prekinitvi zdravljenja z zdravilom Tecfidera razmislite pri bolnikih, pri katerih je število limfocitov več kot 6 mesecev < 0,5 x 109/l.
Consider interruption of therapy until symptoms improve to Grade 1.
Razmislite o prekinitvi zdravljenja, dokler se simptomi ne izboljšajo do stopnje 1.
Consider permanent discontinuation
Razmislite o trajnem prenehanju zdravljenja.
Consider re-initiating at a reduced dose.
Razmisliti je možno o nadaljevanju z zmanjšanim odmerkom.
Consider referral to a dietician to help with a diet plan if necessary.
Razmislite o napotnici za dietetika za pomoč pri prehranskem načrtu, če jo potrebujete.
Consider restarting the next scheduled treatment at 1 dose level reductiona a See table 4 for dose level reductions
Razmislite o ponovnem začetku naslednjega predvidenega zdravljenja z zmanjšanim odmerkom za 1 ravena. a Za ravni zmanjšanja odmerka glejte tabelo 4
Consider resuming at reduced dose if resolves to Grade 0-1.
ponoven začetek zdravljenja z zmanjšanim odmerkom pride v poštev, če se izboljša na stopnjo 0-1
Consider resuming at reduced dose if resolves to Grade 0-1.
Ponoven začetek zdravljenja z zmanjšanim odmerkom pride v poštev, če se izboljša na stopnjo 0-1.
Consider temporarily holding IMBRUVICA.
V takem primeru je treba razmisliti o začasni prekinitvi jemanja zdravila IMBRUVICA.
Consider the benefits and risks before continuing treatment with dabrafenib in patients with a non- cutaneous malignancy that has a RAS mutation.
Pri bolnikih z nekožnim malignomom z mutacijo RAS je treba pred odločitvijo za nadaljevanje zdravljenja z dabrafenibom pretehtati koristi in tveganja takega zdravljenja.
Consider the patient’s full medical history, including any prior or concurrent biological medicine use
Skrbno je treba preučiti celotno anamnezo bolnika, vključno s kakršno koli predhodno ali sočasno uporabo bioloških zdravil.
Consider use of colony- stimulating factor prior to next cycle.
Pred naslednjim ciklom razmislite o uporabi dejavnika za stimulacijo kolonij.
Considerable inter- and intra-individual variability was observed in the pharmacokinetics of raltegravir.
Farmakokinetika raltegravirja se znatno razlikuje tako med bolniki kot pri posameznem bolniku.